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Abstract
Introduction: HIV self-testing (HIVST) was first proposed as an additional option to standard HIV testing services in the
1980s. By 2015, two years after the first HIVST kit was approved for the American market and the year in which Unitaid
invested in the “HIV Self-Testing AfRica (STAR) Initiative,” HIVST remained unexplored with negligible access in low- and mid-
dle-income countries (LMIC). However, rapid progress had been made. This commentary outlines the interlinked market, regu-
latory and policy barriers that had inhibited product development and kept HIVST out of LMIC policy. We detail the
components of STAR that enabled rapid HIVST scale-up, including critical investments in implementation, research, market
forecasting, and engagement with manufacturers and regulators.
Discussion: The STAR Initiative has generated crucial information about how to distribute HIVST products effectively, ethi-
cally and efficiently. Service delivery models range from clinic-based distribution to workplace and partner-delivered
approaches to reach first-time male testers, to community outreach to sex workers and general population “hotspots.” These
data directly informed supportive policy, notably the 2016 WHO guidelines strongly recommending HIVST as an additional
testing approach, and regulatory change through support for WHO prequalification of the first HIVST kit in 2017. In July
2015, only two countries had national HIVST policies and were implementing HIVST. Three years later, 59 countries have poli-
cies, actively implemented in 28, with an additional 53 countries reporting policies under development. By end-November
2018 several quality-assured HIVST products had been registered, including two WHO prequalified tests. STAR Initiative
countries have drafted regulations governing in vitro diagnostics, including HIVST products. With enabling policies, pre-qualifi-
cation and regulations in place, donor procurement of kits has increased rapidly, to a forecasted estimate of 16 million HIVST
kits procured by 2020.
Conclusions: The STAR Initiative provided a strong foundation to introduce HIVST in LMICs and allow for rapid scale-up
based on the wealth of multi-country evidence gathered. Together with sustained coordination and acceleration of market
development work, HIVST can help address the testing gap and provide a focused and cost-effective means to expand access
to treatment and prevention services.
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1 | INTRODUCTION
HIV testing is the gateway to treatment and care and
expanded prevention coverage. The first of the United
Nations’ 90-90-90 Fast Track targets to end the HIV epidemic
calls for 90% of people living with HIV (PLHIV) to know their
HIV status by 2020 [1]. Access to and uptake of HIV testing
services (HTS) in low- and middle-income countries (LMICs)
has increased substantially over the last three decades due to
advances in treatment, rapid testing and greater availability of
HIV testing in facility and community. Despite these advances,
an estimated 25% of PLHIV globally still do not know their
status [2]. In eastern and southern Africa where the HIV bur-
den is greatest, it is estimated that 2.7 million PLHIV still do
not know their status [3,4].
To address these gaps, innovative and strategic approaches
to HIV testing are needed [5]. HIV self-testing (HIVST), has
been highlighted as an additional tool to increase access and
uptake of HIV testing in higher risk populations with low cov-
erage and particularly in environments with high rates of
stigma [6]. In addition, HIVST has the potential to improve
efficiency of the health system by triaging those without HIV
straight to prevention services and freeing up health workers’
time and could consequently reduce costs of HTS [6].
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HIVST was first proposed as an additional option to stan-
dard HTS in the 1980s [7]. By 2015, three years after the
first HIVST kit was approved for the American market [8],
HIVST remained unexplored with negligible access in LMIC.
By the end 2015, only two high-income countries were
actively implementing HIVST services as part of their public
health HIV response primarily in the private sector, and WHO
had yet to state an official position.
In 2013, WHO convened the first global consultation on
HIVST identified that development of the necessary normative
guidance for HIVST was largely hampered by lack of evidence
on safety, acceptability, feasibility and scalability; uncertain dis-
tribution methods for HIVST kits; unclear processes for linking
self-testers to care and treatment; and lack of clarity on meth-
ods for creating demand among target populations [9,10].
As with any new health technology, the introduction of
HIVST kits in LMICs faced several immediate policy, regula-
tory and market challenges [11].
First, because of the lack of WHO prequalified products for
self-test use, opportunities to generate evidence for the public
health benefit and to create demand were limited. Although
the first discussion of HIVST introduction dates back to 1986,
the first HIVST product only became available in 2012 when
OraQuick® In-Home HIV Test (OraSure Technologies, Bethlehem,
Pennsylvania USA) was approved by the US Food and Drug
Administration [8,12]. It was not until mid to late-2015 that
Conformite Europeenne-marked products autotest VIH® (AAZ
Labs, Boulogne-Billancourt France) and BioSURE HIV Self Test
(BioSURE UK Ltd., Essex, England UK) became available for
sale and use in the private sector in the United Kingdom and
France.
Before 2015, there were no HIVST products registered by
national regulatory authorities in Africa [11,13,14]. At that
time, while HIVST was being assessed through controlled
research studies in the region, the market for, and awareness
of, official HIVST in Africa, and LMICs more broadly, was
extremely limited. Without evidence, WHO normative guideli-
nes could not be made to support HIVST introduction – nor
guidance on how it should be implemented, limiting countries’
ability to take on or prioritize HIVST as part of a national
strategy. Furthermore, because of global and national level
policy barriers, there were no regulatory pathways nor clear
data collection systems to assure the quality of the HIVST
products or to monitor the most ethical, acceptable and effec-
tive ways to implement self-testing.
Second, a healthy HIVST market also requires solidified
demand from end-users and buyers including both national
governments and donors. Before 2015, investment from gov-
ernments and large-scale donors was constrained by a lack of
evidence that HIVST could be a safe and effective way to
increase testing rates. Because of this, the President’s Emer-
gency Plan for AIDS Relief (PEPFAR) and the Global Fund to
Fight AIDS, Tuberculosis and Malaria (Global Fund), two of the
biggest procures of HIV test kits globally, had yet to procure
HIVST outside of small quantities for research. At the same
time, little was understood about potential levels of consumer
demand for HIVST, including how consumers would want to
access HIVST and the HIVST product attributes likely to drive
uptake or impact outcomes.
Third, in the absence of HIVST guidelines and clearly
defined quality assurance pathways, governments and donors
had little ability to understand the degree by which various
products met minimum quality standards. Without evidence to
support paying a higher cost for self-tests as opposed to pro-
fessional use products, governments and donors signalled a
very low willingness to pay. As a result, public sector procure-
ment was largely frozen. A competitive market with several
manufacturers has driven down the cost of professional-use
HIV rapid diagnostic tests. While these issues apply to HIVST
kits, they also face further challenges as they must be
designed and packaged for self-test use, which incurs addi-
tional costs, and requires additional approvals and regulations.
Faced with the prospect of low margins, unclear approval
pathways, and limited concrete volumes, manufacturers
responded by minimizing investment and adapting professional
use products for self-testing. In addition, several suppliers with
promising products lacked deep experience operating in LMIC
markets [15].
Addressing the interlinked market, regulatory and policy
barriers that had inhibited HIVST product development
through a comprehensive approach was the goal of the Uni-
taid investment through the HIV Self-Testing AfRica (STAR)
Initiative.
This commentary provides a broad overview of the strate-
gies and achievements of the STAR Initiative in the introduc-
tion of HIVST in LMICs and the development of the HIVST
market and considers the remaining challenges for bringing
HIVST to scale.
2 | DISCUSSION
In 2015 Unitaid invested in a comprehensive effort to develop
the market for HIVST by:
1 Establishing the evidence for its safety, acceptability, feasi-
bility and scalability;
2 Creating an enabling environment with regards to norma-
tive guidelines, national policies, and regulatory frameworks
based on the foundation of research evidence;
3 Generating diverse demand through multiple distribution
channels adapted to the needs of priority populations and
create advocacy for additional financing; and
4 Accelerating market entry for suppliers at affordable and
sustainable prices.
This commitment resulted in the support of the five-year
“HIV Self-Testing in AfRica (STAR) Initiative” with Population
Services International (PSI) and a consortium of partners,
including London School of Hygiene and Tropical Medicine,
Liverpool School of Tropical Medicine, University College Lon-
don, and Society for Family Health (SFH) and the University of
Witwatersrand Reproductive Health and HIV Institute (Wits
RHI) in South Africa, initially in three Southern African countries
(Malawi, Zambia and Zimbabwe), expanding to include South
Africa, Lesotho and Swaziland in 2017 (Figure 1).
2.1 | Evidence framework for safety, acceptability,
feasibility and scalability
An increasingly strong set of evidence from a range of differ-
ent populations and settings, demonstrates that the
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implementation of HIVST is safe, acceptable and effective
when kits are used correctly, and can contribute to increased
HIV testing coverage [6,16,17].
The STAR Initiative partners worked collaboratively to iden-
tify, design and implement a research agenda to inform nor-
mative guidelines, the foundation upon which many national
health policies are based. This was a major turning point for
the creation of an enabling environment since most countries
would not adopt policies for HIVST and donors would not
invest in the product without these guidelines.
The agenda, which was in part funded by other partners,
included formative research and accuracy studies to establish
that HIVST was acceptable, safe, and could be correctly per-
formed by priority populations [18,19]. Further studies tested
user preferences and established simple distribution models
aimed at using HIVST for maximum public health impact
[18,20,21]. Data from these early distribution models
informed costing and cost-effectiveness studies to establish
the evidence for HIVST scalability and sustainability
[20,22,23]. This collaboration helped generate important
aspects of the evidence needed to inform WHO Guidelines on
HIVST and Partner Notification (i.e., HIVST normative guideli-
nes) published in December 2016, and the operational guid-
ance at country level that followed.
2.2 | Creating an enabling environment for national
policies, and regulatory frameworks
The STAR Initiative supported efforts to widely disseminate
the guidelines and contribute to national policy and strategy
development, informing HIVST roll-out across LMICs. As pol-
icy was being established, the STAR Initiative worked with
country governments in Southern Africa through technical
working groups (TWGs) to ensure that research was continu-
ously informing implementation. The TWGs were chaired by
MoHs and included representatives from the national regula-
tory bodies, WHO, in-country donors supporting national HIV
programmes, civil society and PLHIV advocacy and support
groups, as well as PSI and local research partners. To increase
knowledge-sharing across countries and stakeholders, and to
drive development of an enabling environment beyond STAR
countries, the STAR Initiative developed toolkits to guide
research design and HIVST implementation and met on a reg-
ular basis to share experiences. This included direct country
exchanges between STAR Initiative countries and other Afri-
can countries.
The STAR Initiative hosted a pivotal workshop in Nairobi in
April 2017, linked to a WHO regional guidelines workshop, to
share their HIVST implementation experience with MoH
The intervention logic: Impact of HIV Self-Testing
• In Southern and Eastern Africa only an estimated 76% of PLHIV know their status
• Inadequate testing coverage prevents PLHIV from receiving lifesaving treatments and risks further transmissions
• Current testing approach is low among certain population groups and slows down progress in closing the testing gap
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• Limited availability of quality assured HIVST products
• Lack of visibility on potential market size and concrete forecasts
• Lack of substantial demand at country level due to low awareness and limited knowledge to bridge gap between policy and 
implementation
Access 
barriers
Activities Outputs Outcomes Impacts
• Generate demand  for 
HIVST;
• Engage manufacturers;
• Advocate for scale-up at 
country and global level;
• Operational research on 
delivery and impact 
framework.
• Enabling environment 
established with evidence 
to support impact and cost-
effectiveness of HIVST;
• Affordable prices and 
diverse product selection  
in LMICs;
• Increased awareness of 
HIVST.
• Increased demand, access 
and uptake of HIVST in 
LMICs;
• Healthy HIVST market and 
more robust forecasting;
• Greater availability of 
quality- assured HIVST kits;
• Funding for scale-up and 
long-term sustainability.
• Increased number of 
people who know their 
status and linked to ART;
• Reduced morbidity and 
mortality among PLHIV;
• Increased economic 
impact. P
ro
po
se
d 
in
te
rv
en
tio
n
Pr
ob
le
m
 s
ta
te
m
en
t
Figure 1. Unitaid-PSI HIV STAR Project: implementation for impact.
PSI, Population Services International; STAR, Self-Testing AfRica; PLHIV, people living with HIV; HIVST, HIV self-testing; LMIC, low- and middle-
income countries.
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representatives. This workshop provided the information nec-
essary to transform normative guidance into implementation
and led to a series of country implementation visits, catalysing
action across Africa such as MoH tours of STAR implementa-
tion projects to learn directly about challenges and successes
(e.g. eSwatini, Lesotho, Malawi, Uganda, and Zimbabwe). Bots-
wana and Mozambique HIVST policy adoption and/or pilots
were initiated as a result of this meeting. A number of West
African countries (e.g. Co^te d’Ivoire, Mali, and Senegal) were
approved for funding by Unitaid through the ATLAS project to
pilot HIVST shortly after the workshop. Another workshop
was organised in Bangkok in collaboration with Unitaid, WHO
and UNAIDS in October 2018, to share evidence and experi-
ence with HIVST with governments and implementers from
13 countries in Asia and the Pacific including the launch of
the WHO strategic framework on HIVST [24] to accelerate
the introduction and scale-up of HIVST in this region [Meeting
report forthcoming].
To support the operationalization of policy, the STAR Initia-
tive provided technical assistance and held regional workshops
to clarify diagnostic regulatory frameworks and identify the
steps necessary to establish external quality assurance and
post-market surveillance systems for HIVST [25]. As a result,
targeted solutions were developed in each country and
included activities such as establishing medical device commit-
tees, defining responsibilities of regulatory bodies, introducing
laws to parliament for product oversight, and evaluating and
registering products. Harmonization of these regulatory pro-
cesses has been desired since the first diagnostic products
were introduced in Africa.
As a result of these efforts and advocacy, momentum
around HIVST is increasing and many additional countries
have indicated their interest in introducing HIVST.
As of July 2018, 59 countries now have policies explicitly
allowing HIVST, of which 28 are now fully implementing
[26]. In addition, 32 countries are actively piloting HIVST
[26].
2.3 | Generating diverse demand through multiple
distribution channels and advocacy for additional
financing
For a developed and sustainable market, demand for HIVST
products must be generated from end-consumers, MoHs and
donors. The STAR Initiative conducted in-depth research to
understand consumer preferences and provider perceptions
of HIVST and used this evidence to inform and refine the
design of eight facility- and community-based distribution
models in Malawi, Zambia and Zimbabwe [18,20]. In its first
two years, the STAR project showed that community-based
and partner-delivered HIVST can be an effective testing
approach with several advantages that complement conven-
tional options [26,27]. HIVST also demonstrated the ability to
reach those who are not currently accessing services, such as
first-time testers, and facilitated frequent re-testing, particu-
larly among those with high ongoing risk [28]. HIVST may also
improve efficiency and effectiveness of overburdened health
systems, by refocusing testing services and resources on
those with a reactive self-test result in need of confirmatory
testing, thereby increasing the efficiency of conventional test-
ing systems [29].
A concern about HIVST is the need to maximize rapid links
to confirmatory testing and antiretroviral therapy (ART) for
people with reactive tests, in addition to linking those with a
non-reactive test to appropriate and effective prevention ser-
vices, such as pre-exposure prophylaxis (PrEP) and voluntary
medical male circumcision (VMMC). Research and program-
matic data from STAR has demonstrated that HIVST offered
by community mobilizers can increase demand, motivation for
and uptake of VMMC [27]. In a community-based HIVST pro-
ject in Zimbabwe, demand for ART was significantly increased,
with survey data also showing that linkage to confirmatory
testing and ART initiation among those who tested positive
and were not previously on ART ranged between 30% and
46% six weeks after an HIVST campaign [30]. Assuming the
same level of ART initiation among those newly diagnosed,
HIVST is likely to result in additional 60,000 to 230,000
PLHIV receiving life-saving treatment annually from 2020 or
combined total of 110,000 to 460,000 (2019 to 2020), in
addition to significant linkage to appropriate prevention
options, including PrEP [28].
A review of evidence in sub-Saharan Africa, including evi-
dence from the STAR Initiative, indicates that delivery models
have had varying acceptability across different targets [29].
Additional evidence shows that the use of HIVST can be cost-
effective [31]. However, to maximize population health impact
within the budget available, HIVST needs to be targeted
based on the prevalence of undiagnosed HIV, likely HIV inci-
dence, and the overall costs of delivering this testing modality.
For example, with community-based HIVST likely to be cost-
effective if introduced for women having transactional sex and
adult men, provided that the undiagnosed HIV prevalence is
above 3% and when delivered through campaign distribution,
such as every five years [31].
Consistent engagement with MoH, Global Fund and PEP-
FAR through the routine dissemination of the STAR Initiative’s
findings allowed these key partners to integrate HIVST into
longer-term scale-up plans and funding, including within Global
Fund concept notes and PEPFAR country operational plans. In
2018, HIVST was included as a dedicated testing strategy in
PEPFAR country guidance and received a substantial funding
increase. Efforts are also underway to embed HIVST into
domestic health budgets and determine the most cost-effec-
tive way of delivering testing services, including HIVST. For
example, to enable the transition to domestic financing in
South Africa, the potential cost-savings of HIVST will be quan-
tified and incorporated into the HIVST investment case being
developed for the South African National Department of
Health.
2.4 | Accelerating market entry for suppliers at
affordable and sustainable prices
Without normative guidance, demand for HIVST kits was
weak, with uncertain forecasts ranging from 4 to 80 million
tests until 2016. To provide greater clarity on potential
demand, with funding from the Bill and Melinda Gates Foun-
dation (BMGF), PSI developed estimates of the size of the
HIVST market. PSI estimated that by 2020, the market would
reach either 3.3 to 5.7 million or 11 to 15 million tests per
year in nine African countries depending upon whether con-
servative or moderate assumptions were applied [15].
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Based on the “moderate scenario” of the Expanding Access
to HIVST report, which assumes that donors will invest to
support development of both public and private sector mar-
kets, the HIVST market size could be between 13 and 15 mil-
lion kits annually by 2020 [26]. Currently 99 countries had
included HIVST in procurement planning, representing more
than 85% of the global HIV burden. Preliminary estimates
based on these findings suggest HIVST is likely to result in at
least 200,000 to 500,000 additional PLHIV who will know
their status annually.
In order to ensure a high-quality supply of HIVST kits, regu-
lators and manufacturers needed to understand how HIVST
fits into the current regulatory structures. Under the STAR
Initiative, WHO worked to clarify the pre-qualification (PQ)
requirements with manufacturers. By leveraging the accuracy
and usability studies conducted in-country, PSI was able to
identify product and instruction changes needed to achieve
PQ or Global Fund/Unitaid Expert Review Panel for Diagnos-
tics (ERPD) approval and national registration for OraQuick®,
the only product with the evidence required to submit a dos-
sier at the time. Wits RHI simultaneously conducted studies in
South Africa to inform the WHO PQ submissions for several
HIVST products, including blood-based products. However, as
of 2016, significant gaps remained between the available evi-
dence for blood-based HIVST versus oral-fluid HIVST. This gap
had the potential to hinder diverse market supply. With the
support of BMGF, the STAR Initiative conducted consumer
usability studies on four blood-based HIVST products, optimiz-
ing instructions for use, and piloting the use of the most suit-
able blood-based HIVST products [32].
To improve the availability of information about the HIVST
market, Unitaid and WHO developed a series of HIVST land-
scape reports to inform demand, assist with product selection
and application, and incentivize supplier participation [26,33].
The landscape reports included a summary of the key evi-
dence to support the use of HIVST, the current state of
HIVST policy and regulation, and detailed information about
available and pipeline HIVST products. The landscape reports
also included information on HIVST demand.
Despite this progress towards international approvals, man-
ufacturers remain concerned that in some countries the regu-
latory process remains opaque, the responsible authorities for
the registration of HIVST products are still unclear, and even
with WHO PQ, in-country validation and registration are still
required. These complications add to the cost of doing busi-
ness for manufacturers and threaten the sustainability of
affordable prices for HIVST.
3 | REMAINING MARKET CHALLENGES
Despite this growing interest, however, the HIVST market is
still nascent and the current volumes are unlikely to be suffi-
cient to make the LMIC market healthy and attractive to mul-
tiple suppliers. Market conditions are further compounded by
continued ambiguity surrounding forecasting and regulatory
environments. High volumes of demand for HIVST kits, and
HIV testing in general, will be needed to establish the viable
market necessary for long term sustainability of HIVST.
Approximately 2.5 million HIVST kits were sold worldwide
between 2012 and 2017 [33]. In July 2018, the first global
HIVST forecast showed at least 5 million HIVST kits would be
procured by the end of 2018 and that with current donor and
private sector investments the market would reach nearly
20 million kits by 2020 [26].
Currently there are only two WHO prequalified HIVST
products, the INSTI HIV Self Test (bioLytical, Richmond,
British Columbia Canada) and the OraQuick HIV Self-Test
(OraSure Technologies), with others under review [34].
Through the Global Fund/Unitaid ERPD four other HIVST
products, all of which are blood-based, have also become avail-
able for use in the context of operational research and
demonstration projects [35].
While HIVST has been shown to be effective, the invest-
ment in additional testing is being scrutinized. In countries
where the first 90-90-90 target has been reached or nearly
attained, diagnosing the few people with HIV who do not
know their status may be challenging and costly. In countries
with slower progress towards achieving the first 90 target, a
major shift will be needed in the approach to testing to
improve effectiveness and efficiency in finding those with an
undiagnosed HIV infection. There is currently still lacking clar-
ity on how HIVST can fit and contribute to reaching the
remaining PLHIV in need of diagnosis and contributing to
uptake of prevention. Creating an investment case that is
country context specific is critical to the sustainability and
accelerated scale up of HIVST.
Notwithstanding these challenges, the prospects for the
HIVST market in LMICs have improved notably over the last
few years. This is due in no small measure to significant
investments committed by Unitaid and other partners, includ-
ing the BMGF and the Children’s Investment Fund Founda-
tion’s Charitable Support Agreement with OraSure (2017)
which reduced the price of the only WHO Prequalified pro-
duct to US$2 for 50 countries [36]. This agreement is only
valid for four years, and the price may increase if the requisite
volumes are not established and maintained by the end of the
term. An increase in demand and adoption as well as the pres-
ence of other affordable products will reduce this threat and
offer countries a choice in product selection based on the
preferences of different user populations.
Despite having a better understanding of how to deliver
HIVST and an increasing number of countries introducing it,
coverage remains low in comparison to the current need, and
this is due to limited awareness of users and providers. Both
the demand and supply for HIVST remain limited, hindering the
establishment of a healthy market with affordable products.
While the findings from the STAR Initiative have been suc-
cessful in motivating country governments and funding agen-
cies, the need for additional evidence of cost-effectiveness of
the different HIVST delivery models is critical to securing
increased scale-up funding. Likewise, there is the need to
demonstrate the impact of HIVST in enabling countries to
meet their HIV coverage targets as part of the UN 90-90-90
to make a compelling investment case. Increased effectiveness
of HIVST will require a balance between targeting delivery for
high testing coverage for new testers versus benefits from re-
testers. Such a balance is important to achieve efficiencies in
the health system because health services and resources will
be focused on confirmatory testing and linkage to treatment
while those with a negative test can be triaged to prevention
services [6].
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4 | CONCLUSIONS
The STAR Initiative has provided a strong foundation to
introduce HIVST, in LMICs, and allow for rapid scale-up
based on collection of multi-country evidence and rapid dis-
semination to inform policy and practice through national
TWGs, international workshops, and regulators and manufac-
turers fora. The increasingly strong evidence base has shown
that HIVST is preferred by many Africans to all other testing
modalities and can reach those who do not test and are at
high risk of HIV in LMICs. The market for HIVST is expand-
ing and national HIV programmes, with support from exter-
nal donors, are beginning to move beyond the policy and
pilot stage to scale up HIVST through multiple distribution
models. Ensuring an enabling environment with systems and
structures in place that are supportive of HIVST, having safe-
guards in place to keep inferior products out of LMIC mar-
kets, to prevent social harms, and effective targeting of low
cost models for HIVST distribution and linkage into preven-
tion and care services in high prevalence populations will
maximize the important potential for public health impact.
Together with sustained coordination and acceleration of
market development work outside of the Africa region,
HIVST can help address the testing gap and provide a
focused and cost-effective means to expand access to treat-
ment and prevention services.
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